IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study (IMMUNOSABR2)

  • STATUS
    Recruiting
  • End date
    Dec 1, 2023
  • participants needed
    126
  • sponsor
    Maastricht University
Updated on 3 March 2022
platelet count
renal function
cancer
monoclonal antibodies
measurable disease
lung cancer
metastasis
neutrophil count
liver metastasis
pd-l1
stereotactic body radiation therapy
renal function test

Summary

This will be a phase II trial testing if the combination of stereotactic ablative body radiotherapy (SABR) and L19-IL2 improve the progression-free survival in patients with limited metastatic non-small cell lung cancer (NSCLC). The trial consists of one cohort with two arms; C-arm and an E-arm.

Patients with oligometastatic disease will receive SABR to minimal 1 and max all metastatic sites (max 5 sites irradiated) and patients with diffuse metastatic lesions (6 to max 10) will receive radiotherapy to max 5 sites. In the experimental arm, immunotherapy will be given after irradiation.

Description

IMMUNOSABR will include 126 patients. In this single-stage controlled randomised open-label phase II trial, we aim to demonstrate an absolute increase in progression-free survival (primary endpoint). PFS will be determined as the time between randomisation and disease progression, according to RECIST 1.1, death due to any cause or last patient contact alive and progression-free. Patients will be randomized between control (no immunocytokine) and experimental arms (with immunocytokine L19-IL2) in a 1:1 ratio. The accrual period will be 29 months (or 2.41 years), and the minimum follow-up will be 18 months (or 1.5 years), making the total study duration 47 months. Comparison between control and experimental arms will be made using the Log-Rank statistic. This test for superiority will be one-sided with the desired type I error of 0.10 and power of 0.90.

Patients enrolled in the trial will be randomised into the control arm (C-arm) or experimental arm (E-arm).

  • C-arm: Standard of Care (SOC) according to the local and national guidelines: (wait and see or surgery and/or chemotherapy and/or standard (symptomatic) radiotherapy and/or SABR, oligometastatic disease.
  • E-arm: SABR (oligometastatic disease) or radiotherapy (diffuse disease) + L19-IL2 up to 6 cycles (+ aPD(L)1 if SOC)

The expected 1.5-year PFS is 15% in the C-arm and 35% in the E-arm. A sample size of 116 patients (58 patients per treatment arm) is needed to show this difference of 20% in PFS, using a logrank test with a two-sided alpha of 0.05 and power of 85%. Patients will be evenly divided over the two arms. Assuming a drop-out rate of 10%, a total of 126 patients (63 per arm) need to be included.

Primary objective The main objective of the trial is to test if the activity of the combination of (SAB)R and L19-IL2 in patients with metastatic NSCLC will result in improved progression-free survival (PFS) compared to the SOC.

Secondary Objectives

  • Assessment of the PFS of the patient cohort, at 5 years after randomisation.
  • Assessment of the overall survival of the patient cohort, at 5 years after randomisation.
  • To assess the toxicity of this treatment schedule;
  • To assess Quality of Life (QoL);
  • To assess the occurrence of an Out of Field Radio-Immune (OFRI) response / abscopal effect using imaging;
  • To assess the occurrence of an In Field Radio-Immune (IFRI) response using imaging;
  • To perform correlative biomarker studies related to treatment response.

Exploratory endpoints:

  • Correlative biomarker studies:
  • Tumour tissue: e.g EDB expression, non-synonymous mutations, immune monitoring;
  • Blood: e.g. EDB expression, cfDNA, and immune monitoring;
  • Radiomics on CT and if available MRI;
  • Faeces: diversity in microbiota.
  • iRECIST
  • Tumour grow kinetics

Details
Condition NSCLC Stage IV, Metastatic Disease
Treatment Radiation, Darleukin
Clinical Study IdentifierNCT03705403
SponsorMaastricht University
Last Modified on3 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Oligometastatic disease (5 metastases)
Histological confirmed limited metastatic adult NSCLC patients, regardless of the PD-L1 status
Maximum of 5 metastatic lesions, maximum two brain lesion with a total cumulative diameter of 5cm is allowed
SOC baseline imaging e.g MRI and/or PET-CT and CT-brain or MRI brain and/or
CT-scan with at least covering thorax-upper abdomen-brain, within 6 weeks
prior to randomisation
If a patient has unclear lesions in the liver or brain an MRI would be advised
following the ESMO guidelines
In patients with 2 lung tumours, it can be unclear if the patient has 2 concurrent primary tumours or a primary lung tumour with 1 metastasis. In this case, the local multidisciplinary tumour board will decide whether the patient has an M1 disease or not
Previous treatment: Prior cancer treatments are allowed but must be
discontinued for at least 4 weeks before randomisation. In case of maintenance
chemotherapy, this therapy will only be started after the end of the L19-IL2
treatment or only in case of Anti-PD(L)1 treatment, during L19-IL2 therapy
Age of 18 years or older
WHO performance status 0-1
Adequate bone marrow function, evaluated in the local laboratory (Lab): Absolute Neutrophil Count (ANC) of 1.0 x 109 /L, platelet count 100 x 109/L, Haemoglobin (Hb) 6.0 mmol/L (or 9.67 g/dL) (it is allowed to give a blood transfusion if Hb is initially too low)
Adequate hepatic function (evaluated in the local lab): total bilirubin 1.5 x upper limit of normal (ULN) for the institution; ALT, AST, and alkaline phosphatase 2.5 x ULN for the institution or 5 in case of liver metastasis)
Adequate renal function (evaluated in the local lab): creatinine clearance of at least 40 ml/min
Adequate endocrine (TSH, FT4) function, local guidelines
The patient is capable of complying with study procedures
Life expectancy of at least 12 weeks
Negative serum pregnancy test for females of childbearing potential
Signed and dated written informed consent
Ability to comply with contraception requirements
Non-sterilised, sexually active male patient with a female partner who is of
child-bearing age, must use two acceptable birth control methods like a condom
combined with spermicidal cream or gel from the first dose of study medicine
during the study and at least up to 12 weeks after the last administration of
the study medicine and up to 5 months after the last dose of the medicine with
anti-PDL)1 as an action mechanism (if you get this product besides the study
medicine), as an addition to the use, by the female partner, of as described
in the following section
Women of childbearing potential (WOCBP) and WOCBP partners of male patients
must be using, from the screening to three months following the last study
drug administration and 4 5 months after last dose of anti-PD(L)1 maintenance
treatment, effective contraception methods ((a) IUD (IUD) or intrauterine
hormone delivery system (IUS), b) combined (with estrogen and progesterone)
hormonal contraception associated with ovulation inhibition (oral
intravaginal, transdermal), c) hormonal contraception with progesterone only
associated with ovulation inhibition (oral, injectable, implantable), as
defined by the "Recommendations for contraception and pregnancy testing in
clinical trials" issued by the Head of Medicine Agencies' Clinical Trial
Facilitation Group ([www.hma.eu/ctfg.html).](http://www.hma.eu/ctfg.html\).)
Poly-metastatic disease (6 to 10 metastases)
Histological confirmed limited metastatic adult NSCLC patients, regardless of
the PD-L1 status
A minimum of 6 and maximum of 10 metastatic lesions, maximum two brain lesion
with a total cumulative diameter of 5cm is allowed
At least one measurable lesion (according to RECIST 1.1) that has no overlap
with the PTV of the lesion subjected to radiotherapy
Previous treatment: The time between the last administration of chemotherapy
and the randomisation must be at least 4 weeks. In case of maintenance
chemotherapy, this therapy will only be started after the study if e-arm
allowed during c-arm. In case of Anti-PD(L)1 treatment, this is allowed in
both arms, so also during L19-IL2 therapy
Age of 18 years or older
WHO performance status 0-1
Adequate bone marrow function (evaluated in the local lab): Absolute Neutrophil Count (ANC) of 1.0 x 109 /L, platelet count 100 x 109/L, Hb 6.0 mmol/L (or 9.67 g/dL) (it is allowed to give a blood transfusion if Hb is initially too low)
Adequate hepatic function (evaluated in the local lab): total bilirubin 1.5 x upper limit of normal (ULN) for the institution; ALT, AST, and alkaline phosphatase 2.5 x ULN for the institution or 5 in case of liver metastasis)
Adequate renal function (evaluated in the local lab): creatinine clearance of at least 40 ml/min
Adequate endocrine (TSH, FT4) function, local guidelines
The patient is capable of complying with study procedures
Life expectancy of at least 12 weeks
Negative serum pregnancy test for females of childbearing potential
Ability to comply with contraception requirements (see oligo)
Signed and dated written informed consent

Exclusion Criteria

More than 10 metastatic lesions
More than 2 brain metastatic lesions
brain metastases with a cumulative diameter larger than 5 cm
Patients with non-infectious pneumonitis, uncontrolled thyroid disease, pleuritis, pericarditis and peritonitis carcinomatosis
Patients who received live vaccines 30 days or fewer prior to enrolment
Patients who are already actively participating in another study
Patients who need simultaneous radiation on the primary tumour and metastatic lesion(s). For these patients it might be an option to treat the primary tumour first although this is not mandatory for this study. There must be minimal four weeks between last treatment and randomisation
Whole brain radiotherapy (WBRT) is not allowed, although it is accepted when given at least 4 weeks prior to randomisation or after the treatment period. Patients with stable brain metastases are not excluded
Previous radiotherapy to an area that would be re-treated by (SAB)R, resulting in overlap of the high dose areas
Maintenance therapy with Anti-PD(L)1 treatment combined with chemotherapy is not allowed during treatment ((SAB)R and L19-IL2 cycles)
Other active malignancy or malignancy within the last 2 years (except localised skin basal/squamous cell carcinoma, non-muscle invasive carcinoma of the bladder or in situ carcinoma from any site)
Concomitantly administered glucocorticoids may decrease the activity of IL2 and therefore should be avoided. However, patients who develop life-threatening signs or symptoms may be treated with dexamethasone until toxicity resolves or reduces to an acceptable level (generally grade 1 and 2, however must be based at the research physician's discretion)
History of allergy to intravenously administered proteins/peptides/antibodies/ radiographic contrast media
HIV positive; active HIV infection, or active hepatitis B or C (assessed in local lab)
Systemic treatment with either corticosteroid (>10 mg daily prednisone equivalents) or Interferon alpha or immunosuppressive medications within 14 days prior to randomisation. Topical or inhalation steroids are allowed. If a patient needs to take unexpectedly immunosuppressive medication during the trial, it will be allowed but decreasing the dose as soon as possible is strongly advised
Prior history of organ transplant, including autologous stem cell transplant
Acute or sub-acute coronary syndromes within the last year, acute inflammatory heart disease, heart insufficiency NYHA > 2, or irreversible cardiac arrhythmias
A known impaired cardiac function defined as left ventricular ejection fraction (LVEF) < 50 % (or below the study site's lower limit of normal) as measured by MUGA or ECHO
Uncontrolled hypertensive disease; (systolic blood pressure (SBP) 160 or diastolic blood pressure (DBP) 100 mm Hg during two measurements)
History or evidence of active autoimmune disease
Severe diabetic retinopathy (neoangiogenesis targeted by L19 outside the tumour)
Major trauma, including oncologic surgery, but excluding smaller procedures like the placement of porth--cath or surgical biopsy, within 4 weeks prior to randomisation (neoangiogenesis targeted by L19 outside a tumour)
Any underlying mental, medical or psychiatric condition which in the opinion of the investigator will make administration of study drug hazardous or hinder the interpretation of study results. Unstable or serious concurrent uncontrolled medical conditions
Pregnancy or breast feeding; it is well known that ED-B, the target of both L19IL2, is expressed in a variety of fetal tissues. Furthermore, anti-PD(L)1 treatment may increase the risk of immune-mediated disorders. Therefore, it will be contra-indicated for pregnant or lactating women
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note